# LDOC1

## Overview
Leucine Zipper Down-Regulated in Cancer 1 (LDOC1) is a gene that encodes a regulatory protein involved in the modulation of nuclear factor kappa B (NF-κB) signaling, a pathway critical for immune response, cell survival, and inflammation. The LDOC1 protein, characterized by a leucine zipper-like motif and a proline-rich region, functions primarily as a transcriptional regulator and signaling protein (Nagasaki2003Leucine‐zipper; Zhao2020LDOC1). It acts as a negative regulator of NF-κB, inhibiting its activation and thereby maintaining cellular homeostasis and preventing excessive inflammatory responses (Nagasaki2003Leucine‐zipper). LDOC1 is ubiquitously expressed in various human tissues, including the brain, thyroid, heart, kidney, and pancreas, and is implicated in normal cellular functions as well as in the pathogenesis of several cancers, where it often serves as a tumor suppressor (SALEMI2012Expression; Wanka2020LDOC1). Its interactions with proteins such as GNL3L and involvement in pathways like IL-6/JAK2/STAT3 highlight its role in regulating cell growth and apoptosis, making it a potential biomarker and therapeutic target in oncology (Thoompumkal2016Leucine; Lee2019Novel).

## Structure
The LDOC1 protein is characterized by a leucine zipper-like motif at the N-terminal region and a proline-rich region containing an SH3-binding consensus sequence. These motifs are indicative of its role in protein-protein interactions, which are typical of transcription factors and signaling proteins (Nagasaki2003Leucine‐zipper; Zhao2020LDOC1). The leucine zipper motif suggests a potential role in dimerization or interaction with other proteins, facilitating DNA binding, which is common in transcription factors (Zhao2020LDOC1). The proline-rich region may enable interactions with SH3 domain-containing proteins, which are often involved in signaling pathways (Nagasaki2003Leucine‐zipper).

LDOC1 is involved in the regulation of NF-κB signaling, with its expression and localization being significantly altered in cancerous tissues, such as thyroid cancer, where it translocates from the nucleus to the cytoplasm (Zhao2020LDOC1). Despite these insights, specific details about the primary, secondary, tertiary, or quaternary structures of the LDOC1 protein, as well as information on post-translational modifications or splice variant isoforms, are not provided in the available literature (Nagasaki2003Leucine‐zipper; Zhao2020LDOC1).

## Function
LDOC1, or Leucine Zipper Down-Regulated in Cancer 1, is a gene that encodes a protein involved in regulating nuclear factor kappa B (NF-κB) signaling, a critical pathway for immune response, cell survival, and inflammation. In healthy human cells, LDOC1 is ubiquitously expressed in various tissues, including the brain, thyroid, heart, kidney, and pancreas, suggesting its involvement in normal cellular functions (SALEMI2012Expression; Wanka2020LDOC1). The protein is primarily located in the cell nucleus, where it is believed to regulate transcriptional responses mediated by NF-κB, balancing proliferation and apoptosis (Wanka2020LDOC1).

LDOC1 acts as a negative regulator of NF-κB by inhibiting its activation, which is typically induced by factors such as tumor necrosis factor-α (TNF-α) (Nagasaki2003Leucine‐zipper). This inhibition is crucial for maintaining normal cellular homeostasis and preventing excessive inflammatory responses. LDOC1 also interacts with other proteins, such as GNL3L, to modulate NF-κB signaling, leading to reduced cell proliferation and increased apoptosis (Thoompumkal2016Leucine). These interactions highlight LDOC1's role in regulating cell growth and apoptosis, which is essential for normal cellular function and immune homeostasis (Lee2020LDOC1; Thoompumkal2016Leucine).

## Clinical Significance
Alterations in the expression of the LDOC1 gene have been implicated in various cancers, where it often acts as a tumor suppressor. In colorectal cancer (CRC), LDOC1 expression is downregulated, and its overexpression inhibits cell proliferation, migration, and invasion, while promoting apoptosis. This suggests that LDOC1 could serve as a novel biomarker for CRC, providing insights into its diagnosis, treatment, and prognosis (Jiang2019Effects).

In vulvar cancer, LDOC1 expression is associated with poor prognosis. Cytoplasmic expression correlates with decreased ten-year overall survival, while nuclear expression is linked to unfavorable ten-year disease-free survival. These findings suggest that LDOC1 may serve as a negative prognostic marker in vulvar cancer (Wanka2020LDOC1).

In thyroid cancer, particularly papillary thyroid carcinoma (PTC), LDOC1 acts as a tumor suppressor. Its overexpression reduces tumor growth and cell migration, while its ablation promotes these processes. LDOC1's role in suppressing NF-κB signaling is significant in this context (Zhao2020LDOC1).

In hepatocellular carcinoma (HCC), LDOC1 is downregulated, and its expression levels are associated with overall survival and disease progression. Overexpression of LDOC1 in HCC cell lines leads to decreased proliferation and migration, suggesting its potential as a favorable prognostic biomarker (Chen2022Leucine).

## Interactions
LDOC1 interacts with several proteins, influencing various signaling pathways. It physically interacts with guanine nucleotide binding protein-like 3-like (GNL3L), modulating NF-κB signaling by reducing p65 protein levels, which leads to decreased NF-κB dependent transcriptional activity and promotes apoptosis (Thoompumkal2016Leucine). This interaction is confirmed through techniques such as GST pull-down assays and co-immunoprecipitation (Thoompumkal2016Leucine).

In lung cancer, LDOC1 forms complexes with phosphorylated JAK2 (pJAK2) and the E3 ubiquitin ligase LNX1, facilitating the ubiquitination and proteasomal degradation of pJAK2. This interaction suppresses the IL-6/JAK2/STAT3 signaling pathway, which is crucial for cancer progression (Lee2019Novel). The presence of LDOC1 enhances the degradation of pJAK2, thereby inhibiting STAT3 activation (Lee2019Novel).

LDOC1 also interacts with various proteins in hepatocellular carcinoma, including MZF1, PEG10, and GNL3L, potentially influencing cellular processes such as proliferation and apoptosis (Chen2022Leucine). These interactions highlight LDOC1's role as a regulatory protein in multiple cancer-related pathways.


## References


[1. (Wanka2020LDOC1) Giulia Wanka, Elisa Schmoeckel, Doris Mayr, Sophie Fuerst, Christina Kuhn, Sven Mahner, Julia Knabl, Maria Margarete Karsten, Christian Dannecker, Helene H. Heidegger, Aurelia Vattai, Udo Jeschke, and Julia Jueckstock. Ldoc1 as negative prognostic marker for vulvar cancer patients. International Journal of Molecular Sciences, 21(23):9287, December 2020. URL: http://dx.doi.org/10.3390/ijms21239287, doi:10.3390/ijms21239287. This article has 8 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/ijms21239287)

[2. (Zhao2020LDOC1) Shuiying Zhao, Yanyan Zhao, Qingzhu Wang, Zhizhen Li, Xiaojun Ma, Lina Wu, Wen Li, Mengmeng Du, Hongfei Ji, and Guijun Qin. Ldoc1 is differentially expressed in thyroid cancer and display tumor‐suppressive function in papillary thyroid carcinoma. Cell Biology International, 44(4):985–997, January 2020. URL: http://dx.doi.org/10.1002/cbin.11295, doi:10.1002/cbin.11295. This article has 2 citations and is from a peer-reviewed journal.](https://doi.org/10.1002/cbin.11295)

[3. (Jiang2019Effects) Jiayi Jiang, You Li, and Zheng Jiang. Effects of ldoc1 on colorectal cancer cells via downregulation of the wnt/β-catenin signaling pathway. Oncology Reports, April 2019. URL: http://dx.doi.org/10.3892/or.2019.7126, doi:10.3892/or.2019.7126. This article has 2 citations and is from a peer-reviewed journal.](https://doi.org/10.3892/or.2019.7126)

[4. (Thoompumkal2016Leucine) Indu Jose Thoompumkal, Krishnan Rehna, Kumaraswamy Anbarasu, and Sundarasamy Mahalingam. Leucine zipper down-regulated in cancer-1 (ldoc1) interacts with guanine nucleotide binding protein-like 3-like (gnl3l) to modulate nuclear factor-kappa b (nf-κb) signaling during cell proliferation. Cell Cycle, 15(23):3251–3267, November 2016. URL: http://dx.doi.org/10.1080/15384101.2016.1242534, doi:10.1080/15384101.2016.1242534. This article has 19 citations and is from a peer-reviewed journal.](https://doi.org/10.1080/15384101.2016.1242534)

[5. (Chen2022Leucine) Huaping Chen, Siyuan Chen, Chen Chen, Aifeng Li, and Zhixiao Wei. Leucine zipper downregulated in cancer 1 may serve as a favorable prognostic biomarker by influencing proliferation, colony formation, cell cycle, apoptosis, and migration ability in hepatocellular carcinoma. Frontiers in Genetics, July 2022. URL: http://dx.doi.org/10.3389/fgene.2022.900951, doi:10.3389/fgene.2022.900951. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fgene.2022.900951)

[6. (SALEMI2012Expression) MICHELE SALEMI, CONCETTA BARONE, CARMELO ROMANO, FEDERICO RIDOLFO, ROBERTO SALLUZZO, FRANCESCO SCILLATO, CATALDO SCAVUZZO, FILIPPO CARACI, ALDO E. CALOGERO, CORRADO ROMANO, and PAOLO BOSCO. Expression of ldoc1 mrna in leucocytes of patients with down’s syndrome. Journal of Genetics, 91(1):95–98, March 2012. URL: http://dx.doi.org/10.1007/s12041-012-0134-x, doi:10.1007/s12041-012-0134-x. This article has 3 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s12041-012-0134-x)

[7. (Nagasaki2003Leucine‐zipper) Koichi Nagasaki, Christian Schem, Constantin von Kaisenberg, Marco Biallek, Frank Rösel, Walter Jonat, and Nicolai Maass. Leucine‐zipper protein, ldoc1, inhibits nf‐κb activation and sensitizes pancreatic cancer cells to apoptosis. International Journal of Cancer, 105(4):454–458, March 2003. URL: http://dx.doi.org/10.1002/ijc.11122, doi:10.1002/ijc.11122. This article has 59 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1002/ijc.11122)

[8. (Lee2020LDOC1) Chia-Huei Lee, Pin-Feng Hung, Ko-Jiunn Liu, Hsuan-Lien Chung, Wen-Chan Yang, Kai-Cheng Hsu, Tsorng-Harn Fong, Hsiu-Jung Lo, Ya-Ping Chen, Ji-Rui Yang, and Ching-Yu Yen. Ldoc1 suppresses microbe-induced production of il-1β in human normal and cancerous oral cells through the pi3k/akt/gsk-3β axis. Cancers, 12(11):3148, October 2020. URL: http://dx.doi.org/10.3390/cancers12113148, doi:10.3390/cancers12113148. This article has 8 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/cancers12113148)

[9. (Lee2019Novel) Chia-Huei Lee, Ji-Rui Yang, Chih-Yu Chen, Ming-Hsien Tsai, Pin-Feng Hung, Shin-Jih Chen, Shang-Lun Chiang, Han Chang, and Pinpin Lin. Novel stat3 inhibitor ldoc1 targets phospho-jak2 for degradation by interacting with lnx1 and regulates the aggressiveness of lung cancer. Cancers, 11(1):63, January 2019. URL: http://dx.doi.org/10.3390/cancers11010063, doi:10.3390/cancers11010063. This article has 17 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/cancers11010063)